AVIR241220C5000
- 0.05
- 0.000.00%
Atea Pharmaceuticals Newsroom
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2
Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $6.2
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.88
Atea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC Focus
Atea Pharmaceuticals Analyst Ratings
Hold Rating on Atea Pharmaceuticals Amidst Competitive Landscape and Market Uncertainties
Hold Rating on Atea Pharmaceuticals: Analysis of Clinical Programs, Financial Health and Future Prospects
Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
Atea Pharmaceuticals (AVIR) Gets a Hold From J.P. Morgan
JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating
JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8
SVB Securities Reaffirms Their Hold Rating on Atea Pharmaceuticals (AVIR)
SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating
Atea Pharmaceuticals (AVIR) Receives a Hold From SVB Securities
Atea Pharmaceuticals Analyst Ratings
SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6
Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)